Duchenne Muscular Dystrophy

About duchenne muscular dystrophy

Duchenne muscular dystrophy (DMD) is a genetic neuromuscular disorder characterised by progressive muscle weakness and wasting1. It is caused by mutations in the dystrophin gene on the X-chromosome which result in an absence of the dystrophin protein1, a protein that helps keep muscle cells intact2

It is the most prevalent neuromuscular disorder, affecting up to 1 out of 3,600 male births worldwide1. Symptoms usually appear during in early childhood, between the ages 3 and 5. The disease primarily affects boys, but can also affect girls as well2, although this is quite rare. The standard therapy that can delay DMD progression is based on corticosteroids. The two mainly used in DMD are deflazacort and prednisone/prednisolone1,3


1. Duchenne Muscular Dystrophy: From Diagnosis to Therapy
    Falzarano, M.S. et al., Molecules, 2015.

2. Duchenne Muscular Dystrophy (DMD)
    MDA, cited on 13/03/2018.

3. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management
    Bushby, K. et al.,The Lancet, 2010.

  1. Calcort (deflazacort)
    Calcort (deflazacort)
    by Merrell Dow/Henning
    for Duchenne Muscular Dystrophy
View as Grid List

1 Item

per page
Set Descending Direction

One more step before you can continue

Our service contains information about acquiring medicines that have been approved in another country. This includes professional information such as approval details, product information and pricing. By scrolling, you are declaring that you are requesting any such information.

Scroll down.

No, I'd like to receive general information only.

Disclaimer: The information TSM provides is aimed at patients with terminal and life-debilitating diseases, their doctors and healthcare professionals. It supports an informed decision by the treating doctor about the patient’s treatment and the consideration of a medicine which has not been approved in the patient’s country.